New drug cocktail aims to tackle tough lymphoma

NCT ID NCT07195799

Recruiting now Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests a combination of the drug linperlisib plus three older drugs (cyclophosphamide, prednisone, and thalidomide) in 180 adults with non-Hodgkin lymphoma that has returned or not responded to treatment. The goal is to see how many patients achieve a complete or partial response. Participants take the drugs in cycles over six months, with longer linperlisib use if they respond.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Linperlisib combined with cyclophosphamide, prednisone, and thalidomide
What this could lead to: If successful, this could offer a new treatment option for people with hard-to-treat non-Hodgkin lymphoma that has come back or not responded to prior therapy.
What could go wrong: This is an early Phase 2 study with only 180 participants, so results may not apply to everyone. The combination has known side effects like infection, fatigue, and blood cell changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia extranodal nasal NK/T cell lymphoma follicular lymphoma mantle cell lymphoma marginal zone lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

The First Affiliated Hospital with Nanjing Medical University
RECRUITING

Nanjing, Jiangsu, 210029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.